Agios Pharmaceuticals
AGIO
120 hedge funds and large institutions have $1.5B invested in Agios Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 17 closing their positions.
124% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 17
39% more capital invested
Capital invested by funds: $1.08B → $1.5B (+$420M)
21% more funds holding
Funds holding: 99 → 120 (+21)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 33
51% less call options, than puts
Call options by funds: $6.06M | Put options by funds: $12.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$59.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.52M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$46.7M |
| 2 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$35.6M |
| 3 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$11.4M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
-$10.9M |
| 5 |
GE
General Electric
Evendale,
Ohio
|
-$7.54M |
AGIO Hedge Fund Activity: Q3 2014 in Review
120 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2014, worth a combined $1.5B — up 39% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AGIO positions and 17 closed out — a net gain of 21 holders — while 32 added to existing stakes and 33 trimmed.
The largest buyer was BB Biotech, adding an estimated $59.7M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $46.7M sold.
- 120 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2014, up from 99 in Q2 2014.
- Funds reported $1.5B of Agios Pharmaceuticals stock for Q3 2014, up 39% quarter-over-quarter.
- 38 funds opened new Agios Pharmaceuticals positions in Q3 2014 and 17 closed out, a net change of +21 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2014 was BB Biotech, an estimated $59.7M added.
- The largest Agios Pharmaceuticals seller in Q3 2014 was T. Rowe Price Associates, an estimated $46.7M sold.
Based on aggregated 13F filings for Q3 2014.